Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcinoma: a multicenter, single-arm, phase II trial

吉西他滨 医学 肿瘤科 养生 放射治疗 内科学 临床终点 化疗 临床研究阶段 胰腺导管腺癌 胰腺癌 临床试验 生物标志物 联合疗法 生存分析 化疗方案 原发性肿瘤 存活率 总体生存率 癌症 腺癌 肿瘤微环境 联合化疗 无进展生存期 外科 放化疗
作者
Ke Cheng,Chenyan Zhang,Jiaxin Liu,Huanji Xu,Jitao Zhou,Zixing Huang,Qiting Wu,Yi Zhang,Ping Chen,Weikang Shao,Zhiping Li,Ye Chen,Gang Zhao,Yi Cheng,Yu Yang,Xin You,Wenhao Guo,Xiaofen Li,Wanting Hou,Xiaoying Li
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
标识
DOI:10.1158/1078-0432.ccr-26-1824
摘要

PURPOSE: The prognosis for metastatic pancreatic ductal adenocarcinoma (mPDAC) remains dismal. In this multicenter, single-arm, phase II study, we evaluated the combination of serplulimab, gemcitabine plus nab-paclitaxel, and radiotherapy (ICSBR regimen) as first-line treatment for mPDAC patients (ChiCTR2300073237). METHODS: Patients with mPDAC were enrolled in the first-line setting. The treatment regimen consisted of serplulimab and gemcitabine plus nab-paclitaxel administered in 21-day cycles, combined with stereotactic body radiotherapy directed at the primary or metastatic sites during cycle 2. Additionally, comprehensive biomarker analysis was conducted. The primary endpoint was the 6-month progression-free survival (PFS) rate, with a predefined target of 60%. RESULT: Forty-six patients received at least one dose of treatment. The 6-month PFS rate was 78.3% (95% CI, 67.2%-91.1%). The median PFS and overall survival (OS) were 8.5 months (95% CI, 7.3-12.0 months) and 14.0 months (95% CI, 12.0 months-not reached), respectively. The objective response rate was 73.9% (95% CI, 58.9%-85.7%). The combination treatment was well tolerated, and no treatment-related deaths or unexpected safety signals were observed. Notably, patients with baseline ctDNA negativity achieved a better survival. Moreover, tumor microenvironment (TME) analysis revealed that baseline fibroblast activation protein-positive cancer-associated fibroblast and T-cell proportions in tumor tissue correlated with clinical outcomes, with distinct spatial distribution and interaction tendencies observed among patients with different responses. CONCLUSION: Overall, the ICSBR regimen demonstrated a promising survival benefit as first-line treatment for mPDAC. Furthermore, ctDNA status and TME analysis highlighted potential markers for guiding precision treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
斯文败类的应助被王新涛采纳,获得10
刚刚
刚刚
2339822272发布了新的文献求助10
刚刚
我是谁的应助被小胖采纳,获得30
1秒前
充电宝的应助被云晓采纳,获得10
2秒前
充电宝的应助被阿楠采纳,获得10
2秒前
yyt完成签到 ,获得积分10
2秒前
爆米花的应助被dan1029采纳,获得10
2秒前
Hello的应助被dan1029采纳,获得10
2秒前
李爱国的应助被dan1029采纳,获得10
2秒前
CodeCraft的应助被dan1029采纳,获得10
2秒前
2秒前
小蘑菇的应助被dan1029采纳,获得10
2秒前
2秒前
万能图书馆的应助被dan1029采纳,获得10
2秒前
Akim的应助被dan1029采纳,获得10
3秒前
sss完成签到 ,获得积分10
3秒前
李健的应助被dan1029采纳,获得10
3秒前
斯文雁易完成签到,获得积分10
3秒前
爆米花的应助被dan1029采纳,获得10
3秒前
04d的应助被dan1029采纳,获得10
3秒前
3秒前
啊吼吼完成签到,获得积分10
3秒前
3秒前
专注的半雪完成签到,获得积分10
3秒前
烟花的应助被CWJ采纳,获得10
3秒前
3秒前
黑米完成签到,获得积分10
3秒前
3秒前
Akim的应助被Crush采纳,获得10
4秒前
04d的应助被心碎的小蛋挞采纳,获得10
4秒前
4秒前
归海子轩完成签到 ,获得积分10
4秒前
dxt完成签到,获得积分10
5秒前
zhangyupei的应助被lemontea采纳,获得10
5秒前
5秒前
LLLTB发布了新的文献求助10
6秒前
Min完成签到,获得积分10
6秒前
YULE完成签到,获得积分10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180713
求助须知:如何正确求助?哪些是违规求助? 9570752
关于积分的说明 21814119
捐赠科研通 7776960
什么是DOI,文献DOI怎么找? 3433298
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479287